| Abstract | A clinically refractory case of cutaneous sarcoidosis was successfully treated with infliximab infusion therapy at a dose of 5mg/kg. Skin lesions cleared dramatically and remain resolved during a 3(1/2) year follow-up, the longest follow-up reported to date. Ongoing biological drug therapy has been administered at a frequency of every 8-10 weeks. Despite cost and safety concerns, infliximab should be considered in cases of cutaneous sarcoidosis refractory to standard treatment protocols. |
| Authors | Ted Rosen, Christy Doherty
(Affiliation: Departments of Dermatology, Baylor College of Medicine and Veterans Affairs Medical Center Houston, Texas, USA.)
|
| Journal | Dermatology online journal
(Dermatol Online J)
Vol. 13
Issue 3
Pg. 14
( 2007)
ISSN: 1087-2108 United States |
| PMID | 18328208
(Publication Type: Case Reports, Journal Article)
|
| Chemical References |
- Antibodies, Monoclonal
- Dermatologic Agents
- Tumor Necrosis Factor-alpha
- infliximab
|
| Topics |
- Antibodies, Monoclonal
(administration & dosage)
- Biopsy
- Dermatologic Agents
(administration & dosage)
- Diagnosis, Differential
- Drug Administration Schedule
- Female
- Follow-Up Studies
- Humans
- Infusions, Intravenous
- Middle Aged
- Nose Diseases
(drug therapy, pathology)
- Sarcoidosis
(drug therapy, pathology)
- Skin Diseases
(drug therapy, pathology)
- Time Factors
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors)
|
